These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37104214)

  • 1. Proton-Pump Inhibitors and Serum Concentrations of Uremic Toxins in Patients with Chronic Kidney Disease.
    El Chamieh C; Larabi IA; Laville SM; Jacquelinet C; Combe C; Fouque D; Laville M; Frimat L; Pecoits-Filho R; Lange C; Stengel B; Alencar De Pinho N; Alvarez JC; Massy ZA; Liabeuf S;
    Toxins (Basel); 2023 Apr; 15(4):. PubMed ID: 37104214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
    Lu S; Zhao J; Chen X; Xu S; Yang X; Zhang Y; Ma Z; Jiang H; Zhou H
    Chem Biol Interact; 2022 Dec; 368():110219. PubMed ID: 36243147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury.
    André C; Bennis Y; Titeca-Beauport D; Caillard P; Cluet Y; Kamel S; Choukroun G; Maizel J; Liabeuf S; Bodeau S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122234. PubMed ID: 32615535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Dental Scores and Saliva Uremic Toxins.
    Rigothier C; Catros S; Bénard A; Samot J; Quintin O; Combe C; Larabi I; Massy Z; Alvarez JC
    Toxins (Basel); 2023 Nov; 15(11):. PubMed ID: 37999529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between Saliva Levels and Serum Levels of Free Uremic Toxins in Healthy Volunteers.
    Fabresse N; Larabi IA; Abe E; Lamy E; Rigothier C; Massy ZA; Alvarez JC
    Toxins (Basel); 2023 Feb; 15(2):. PubMed ID: 36828466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of protein-bound uremic toxins for heart failure in patients with chronic kidney disease.
    Zwaenepoel B; De Backer T; Glorieux G; Verbeke F
    ESC Heart Fail; 2024 Feb; 11(1):466-474. PubMed ID: 38041505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
    Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
    Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients.
    Lu YC; Wu CC; Tsai IT; Hung WC; Lee TL; Hsuan CF; Yu TH; Wei CT; Chung FM; Lee YJ; Wang CP
    Clin Chim Acta; 2021 May; 516():83-91. PubMed ID: 33508250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Chen Y; Zelnick LR; Huber MP; Wang K; Bansal N; Hoofnagle AN; Paranji RK; Heckbert SR; Weiss NS; Go AS; Hsu CY; Feldman HI; Waikar SS; Mehta RC; Srivastava A; Seliger SL; Lash JP; Porter AC; Raj DS; Kestenbaum BR;
    Am J Kidney Dis; 2021 Aug; 78(2):226-235.e1. PubMed ID: 33421453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
    Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
    JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?
    Liabeuf S; Glorieux G; Lenglet A; Diouf M; Schepers E; Desjardins L; Choukroun G; Vanholder R; Massy ZA;
    PLoS One; 2013; 8(6):e67168. PubMed ID: 23826225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients.
    André C; Mernissi T; Choukroun G; Bennis Y; Kamel S; Liabeuf S; Bodeau S
    Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.
    Snauwaert E; Van Biesen W; Raes A; Holvoet E; Glorieux G; Van Hoeck K; Van Dyck M; Godefroid N; Vanholder R; Roels S; Walle JV; Eloot S
    Pediatr Nephrol; 2018 Feb; 33(2):315-323. PubMed ID: 28939943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
    Hart E; Dunn TE; Feuerstein S; Jacobs DM
    Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
    Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
    Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota and Uremic Retention Solutes in Adults With Moderate CKD: A 6-Day Controlled Feeding Study.
    Wiese GN; Biruete A; Stremke ER; Lindemann SR; Jannasch A; Moorthi RN; Moe SM; Swanson KS; Cross TW; Hill Gallant KM
    J Ren Nutr; 2024 Jan; 34(1):26-34. PubMed ID: 37468049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease.
    Claro LM; Moreno-Amaral AN; Gadotti AC; Dolenga CJ; Nakao LS; Azevedo MLV; de Noronha L; Olandoski M; de Moraes TP; Stinghen AEM; Pécoits-Filho R
    Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30249039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.